HPLC法测定蔓荆子黄素的含量

以蔓荆子黄素为指标,用反相 ＨＰＬＣ法测定了蔓荆子中的含量,实验采用 Ｃ_(１８)柱,以甲醇－０．４％磷酸溶液（６０： ４０）为流动相,检测波长 ２５８ｎｍ,用外标法测定,回收率为 ９８．１８％,ＲＳＤ１．４６％,线性范围 ０．１５～０．７５μｇ。本法快速简便,重现性好,为蔓荆子质量控制提供了可靠的依据。     

左室重量与左心功能不全相关性的研究

目的：研究可否用左室重量表达并判定左心功能不全的可能性。方法：将左心功能不全按NYHA标准分成4个级别,每级1组,并设正常对照组,用超声心动图测量同一个病人的左室射血分数（LVEF）和左室重量。用SAS统计软件做方差分析。结果：LVEF与左心功能不全高度负相关（R＝－0．77270）,左室重量与左心功能不全高度正相关（R＝0．73421）。LVEF、左室重量各级指标间差别显著（n＝153,F＝64．85,P＜0．01;n＝153,F＝53．39,P＜0．0001）。各级与对照组比统,LVEF指标从Ⅱ级开始方有显著差别（P＜0．05）;而左室重量指标从Ⅰ级开始就有显著差别（P＜0．05）。结论：LVEF与左室重量指标均与左心功能不全高度相关,但心功能Ⅰ级的病人,左室重量指标更为敏感。     

晶状体上皮细胞PAI—1蛋白酶mRNA的表达

研究从转录水平确定晶状体上皮细胞是否能够合成纤麦原激活物抑制物－１蛋白酶。方法体外培养的牛晶状体上皮细胞,当细胞生长融合后,抽提ＲＮＡ;采用Ｎｏｔｈｅｒｎｂｌｏｔ分析技术,对抽提得到的牛晶状体上皮细胞ＲＮＡ用特异的ｃＤＮＡ探针进行检测。结果在牛晶状体上皮细胞的基因转录产物中存在有ＰＡＩ－１ｍＲＮＡ的表达,所表达的ＰＡＩ－１ｍＲＮＡ碱基长度为２．３ｋｂ。结论牛晶状体上皮细胞能够分泌ＰＡＩ－１蛋白酶：     

睫状体冷冻术联合巩膜穿刺术治疗绝对期青光眼

目的评价睫状体冷冻术联合巩膜穿刺术在治疗绝对期青光眼中的应用。方法对绝对期青光眼４７眼施行睫状体冷冻术联合巩膜穿刺术,观察术后３ａ内眼压变化。结果全部病例术后高眼压症都获缓解,对术后早期眼压反弹,本术较单纯施行睫状体冷冻术者控制眼压疗效好（Ｐ＜０．０１）,且无副作用和并发症。结论睫状体冷冻术联合巩膜穿刺术是治疗绝对期青光眼更简便、安全、有效的手术选择。     

Metabolism of liriodendrin and syringin by human intestinal bacteria and their relation toin vitro cytotoxicity

When liriodendrin or syringin was incubated for 24 h with human intestinal bacteria, two metabolites, (+)-syringaresinol-beta-D-glucopyranoside and (+)-syringaresinol, from liriodendrin and one metabolite, synapyl alcohol, from syringin were produced. The metabolic time course of liriodendrin was as follows: at early time, liriodendrin was converted to (+)-syringaresinol-beta-D-glucopyranoside, and then (+)-syringaresinol. The in vitro cytotoxicities of these metabolites, (+)-syringaresinol and synapyl alcohol, were superior to those of liriodendrin and syringin.     

慢性肾衰继发性甲旁亢iPTH水平变化的临床意义及罗钙全疗效观察

目的探讨慢性肾功能衰竭(CRF)并发继发性甲状旁腺机能亢进(SHPT)血中全段甲状旁腺激素(iPTH)水平变化的临床意义及小剂量罗钙全对慢性肾衰继发甲旁亢早期的疗效观察。方法分别采用免疫放射法、苦味酸法、偶氮胂Ⅲ法、直接紫外法测定60例健康体检者和94例CRF患者血iPTH、Cr、Ca、P含量;取iPTH含量87.5～295ng/L的SHPT病人随机分为观察组和治疗组各23例,治疗组每天口服罗钙全0.25ug。结果血iPTH水平随肾功能损害的加重而逐渐升高,与Cr成正相关,P亦逐渐升高,Ca则逐渐降低;治疗组服药3个月后,血iPTH显著降低(P<0.05),Ca明显升高(P<0.05),P无显著性差异(P>0.05),观察组血iPTH显著升高(P<0.05)。结论iPTH可作为早期诊断CRF继发性甲旁亢的敏感指标且其水平与肾功能损害程度一致;口服小剂量罗钙全治疗早期SHPT的疗效与iPTH水平有关。     

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

PURPOSE: For cancer patients receiving cytotoxic chemotherapy, hepatitis B virus (HBV) reactivation is a well described complication resulting in varying degrees of liver damage. The objectives of this study were to assess the efficacy of the antiviral agent lamivudine in reducing the incidence of HBV reactivation and diminishing morbidity and mortality of cancer patients with chronic HBV infection during chemotherapy. PATIENTS AND METHODS: Two groups were compared in this nonrandomized study. The prophylactic lamivudine group consisted of 65 patients in a phase II study who were treated with lamivudine before and until 8 weeks after discontinuing chemotherapy. The historical controls consisted of 193 consecutive patients who underwent chemotherapy without prophylactic lamivudine. Significant prognosticators for the development of HBV reactivation were determined based on data from the controls. Potential confounding factors were identified between the two groups. The outcomes were compared. RESULTS: In the controls, lymphoma and anthracycline usage were factors identified to be associated with reactivation. The two groups were comparable in most baseline characteristics, although in the prophylactic lamivudine group, there were significantly more patients with lymphoma and receiving anthracyclines. In the prophylactic lamivudine group, there was significantly less HBV reactivation (4.6% v 24.4% in the controls; P <.001), fewer incidences of hepatitis (17.5% v 44.6%; P <.0001) that were less severe (4.8% v 18.7%; P =.0005), and less disruption of chemotherapy (15.4% v 34.6%; P =.0029). The reduction in overall mortality was not statistically different. CONCLUSION: Prophylactic lamivudine significantly reduced the incidence of HBV reactivation and the overall morbidity of cancer patients undergoing chemotherapy.